Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DOMINIC JOHN TITONE

Allopathic & Osteopathic Physicians Internal Medicine Critical Care Medicine

NPI
1184816159
CMS profile
1109025
Location
LAKEWOOD, CO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$61.33

4 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $61.33 4

By paying entity

PY2020 · entire year · sorted by reported total

Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DOMINIC JOHN TITONE

NPI 1184816159 · CMS profile ID 1109025

Allopathic & Osteopathic Physicians / Internal Medicine / Critical Care Medicine

LAKEWOOD, CO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1184816159?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DOMINIC JOHN TITONE, NPI 1184816159, CMS profile ID 1109025. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1184816159?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). DOMINIC JOHN TITONE, NPI 1184816159, CMS profile ID 1109025. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1184816159?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
DOMINIC JOHN TITONE, NPI 1184816159, CMS profile ID 1109025, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1184816159?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

4 matching records · $61.33 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 4 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–4 of 4.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Sunovion Pharmaceuticals Inc. $16.9806/16/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748402823 CMS
AstraZeneca Pharmaceuticals LP $15.2002/20/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736409569 CMS
Bayer HealthCare Pharmaceuticals Inc. $17.3602/14/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 713635493 CMS
GlaxoSmithKline, LLC. $11.7901/25/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738550131 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $166.08 11
PY2020 $61.33 4
PY2021 $56.81 4
PY2022 $41.92 2
PY2023 $1,906.18 9
PY2024 $317.03 11
PY2025 $2,082.80 11

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $428,478.86 96
PY2024 Principal investigator $715,381.10 49
PY2023 Principal investigator $766,726.52 505

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

505 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Genentech, Inc. $4,698.00 12/22/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1040288847
Principal investigator 1 ModernaTX, Inc. $1,070.89 12/14/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042287675
Principal investigator 1 ModernaTX, Inc. $1,070.89 12/14/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042287691
Principal investigator 1 ModernaTX, Inc. $1,070.89 12/14/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042287719
Principal investigator 1 ModernaTX, Inc. $1,070.89 12/14/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042287737
Principal investigator 1 ModernaTX, Inc. $1,070.89 12/14/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042287739
Principal investigator 1 ModernaTX, Inc. $1,070.89 12/14/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042287741
Principal investigator 1 ModernaTX, Inc. $1,070.89 12/14/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042287753
Principal investigator 1 ModernaTX, Inc. $1,070.89 12/14/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042287807
Principal investigator 1 ModernaTX, Inc. $1,070.89 12/14/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042287819
Principal investigator 1 ModernaTX, Inc. $1,070.89 12/14/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042287871
Principal investigator 1 ModernaTX, Inc. $1,070.89 12/14/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042287873
Principal investigator 1 ModernaTX, Inc. $1,070.89 12/14/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042287889
Principal investigator 1 ModernaTX, Inc. $1,070.89 12/14/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042287915
Principal investigator 1 ModernaTX, Inc. $1,070.89 12/14/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042287967
Principal investigator 1 ModernaTX, Inc. $1,070.89 12/14/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042288133
Principal investigator 1 ModernaTX, Inc. $1,070.89 12/14/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042288135
Principal investigator 1 ModernaTX, Inc. $1,070.89 12/14/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042288137
Principal investigator 1 ModernaTX, Inc. $1,070.89 12/14/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042288197
Principal investigator 1 ModernaTX, Inc. $1,070.89 12/14/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042288247
Principal investigator 1 Genentech, Inc. $2,349.00 12/08/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1040288537
Principal investigator 1 ModernaTX, Inc. $101.25 12/07/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042287465
Principal investigator 1 ModernaTX, Inc. $270.00 12/07/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042287477
Principal investigator 1 ModernaTX, Inc. $270.00 12/07/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042287501
Principal investigator 1 ModernaTX, Inc. $270.00 12/07/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042287503
Principal investigator 1 ModernaTX, Inc. $101.25 12/07/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042287505
Principal investigator 1 ModernaTX, Inc. $270.00 12/07/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042287507
Principal investigator 1 ModernaTX, Inc. $101.25 12/07/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042287509
Principal investigator 1 ModernaTX, Inc. $101.25 12/07/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042287511
Principal investigator 1 ModernaTX, Inc. $270.00 12/07/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042287513
Principal investigator 1 ModernaTX, Inc. $270.00 12/07/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042287515
Principal investigator 1 ModernaTX, Inc. $270.00 12/07/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042287517
Principal investigator 1 ModernaTX, Inc. $101.25 12/07/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042287519
Principal investigator 1 ModernaTX, Inc. $101.25 12/07/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042287521
Principal investigator 1 ModernaTX, Inc. $270.00 12/07/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042287523
Principal investigator 1 ModernaTX, Inc. $101.25 12/07/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042287525
Principal investigator 1 ModernaTX, Inc. $101.25 12/07/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042287529
Principal investigator 1 ModernaTX, Inc. $270.00 12/07/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042287531
Principal investigator 1 ModernaTX, Inc. $101.25 12/07/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042287533
Principal investigator 1 ModernaTX, Inc. $101.25 12/07/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042287535
Principal investigator 1 ModernaTX, Inc. $101.25 12/07/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042287537
Principal investigator 1 ModernaTX, Inc. $101.25 12/07/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042287541
Principal investigator 1 ModernaTX, Inc. $270.00 12/07/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042287543
Principal investigator 1 ModernaTX, Inc. $101.25 12/07/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042287545
Principal investigator 1 ModernaTX, Inc. $101.25 12/07/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042287547
Principal investigator 1 ModernaTX, Inc. $270.00 12/07/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042287549
Principal investigator 1 ModernaTX, Inc. $270.00 12/07/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042287551
Principal investigator 1 ModernaTX, Inc. $101.25 12/07/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042287553
Principal investigator 1 ModernaTX, Inc. $270.00 12/07/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042287555
Principal investigator 1 ModernaTX, Inc. $270.00 12/07/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042287561
Principal investigator 1 ModernaTX, Inc. $101.25 12/07/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042287563
Principal investigator 1 ModernaTX, Inc. $270.00 12/07/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042287565
Principal investigator 1 ModernaTX, Inc. $101.25 12/07/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042287569
Principal investigator 1 ModernaTX, Inc. $270.00 12/07/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042287571
Principal investigator 1 ModernaTX, Inc. $101.25 12/07/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042287573
Principal investigator 1 ModernaTX, Inc. $101.25 12/07/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042287575
Principal investigator 1 ModernaTX, Inc. $101.25 12/07/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042287579
Principal investigator 1 ModernaTX, Inc. $270.00 12/07/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042287581
Principal investigator 1 ModernaTX, Inc. $270.00 12/07/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042287587
Principal investigator 1 ModernaTX, Inc. $270.00 12/07/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042287589
Principal investigator 1 ModernaTX, Inc. $270.00 12/07/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042287591
Principal investigator 1 ModernaTX, Inc. $101.25 12/07/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042287593
Principal investigator 1 ModernaTX, Inc. $270.00 12/07/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042287595
Principal investigator 1 ModernaTX, Inc. $101.25 12/07/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042287599
Principal investigator 1 ModernaTX, Inc. $101.25 12/07/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042287601
Principal investigator 1 ModernaTX, Inc. $101.25 12/07/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042287603
Principal investigator 1 ModernaTX, Inc. $270.00 12/07/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042287605
Principal investigator 1 ModernaTX, Inc. $101.25 12/07/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042287607
Principal investigator 1 ModernaTX, Inc. $270.00 12/07/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042287609
Principal investigator 1 ModernaTX, Inc. $101.25 12/07/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042287611
Principal investigator 1 ModernaTX, Inc. $270.00 12/07/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042287613
Principal investigator 1 ModernaTX, Inc. $270.00 12/07/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042287617
Principal investigator 1 ModernaTX, Inc. $101.25 12/07/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042287619
Principal investigator 1 ModernaTX, Inc. $101.25 12/07/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042287621
Principal investigator 1 ModernaTX, Inc. $101.25 12/07/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042287623
Principal investigator 1 ModernaTX, Inc. $270.00 12/07/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042287627
Principal investigator 1 ModernaTX, Inc. $270.00 12/07/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042287629
Principal investigator 1 ModernaTX, Inc. $270.00 12/07/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042287635
Principal investigator 1 ModernaTX, Inc. $270.00 12/07/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042287637
Principal investigator 1 ModernaTX, Inc. $270.00 12/07/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042287639
Principal investigator 1 ModernaTX, Inc. $270.00 12/07/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042287641
Principal investigator 1 ModernaTX, Inc. $270.00 12/07/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042287643
Principal investigator 1 ModernaTX, Inc. $101.25 12/07/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042287645
Principal investigator 1 ModernaTX, Inc. $101.25 12/07/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042287647
Principal investigator 1 ModernaTX, Inc. $101.25 12/07/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042287653
Principal investigator 1 ModernaTX, Inc. $2,680.00 12/04/2023 Non-covered Recipient Entity
Critical Care, Pulmonary and Sleep Associates - CCT - Avacare - HyperCore - PPDS
A Phase 3, Partly Randomized, Observer-blind Study to Evaluate the Immunogenicity and Safety of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in High-risk Adults No dispute reported 06/30/2026 1042050283
Principal investigator 1 ModernaTX, Inc. $545.06 11/28/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042286579
Principal investigator 1 ModernaTX, Inc. $1,070.89 11/28/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042286581
Principal investigator 1 ModernaTX, Inc. $1,070.89 11/28/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042286583
Principal investigator 1 ModernaTX, Inc. $1,070.89 11/28/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042286585
Principal investigator 1 ModernaTX, Inc. $545.06 11/28/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042286587
Principal investigator 1 ModernaTX, Inc. $1,070.89 11/28/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042286589
Principal investigator 1 ModernaTX, Inc. $545.06 11/28/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042286591
Principal investigator 1 ModernaTX, Inc. $1,070.89 11/28/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042286593
Principal investigator 1 ModernaTX, Inc. $545.06 11/28/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042286595
Principal investigator 1 ModernaTX, Inc. $545.06 11/28/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042286597
Principal investigator 1 ModernaTX, Inc. $545.06 11/28/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042286599
Principal investigator 1 ModernaTX, Inc. $545.06 11/28/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042286601
Principal investigator 1 ModernaTX, Inc. $545.06 11/28/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042286603
Principal investigator 1 ModernaTX, Inc. $545.06 11/28/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042286605
Principal investigator 1 ModernaTX, Inc. $545.06 11/28/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042286607
Principal investigator 1 ModernaTX, Inc. $1,070.89 11/28/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042286609
Principal investigator 1 ModernaTX, Inc. $545.06 11/28/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042286611
Principal investigator 1 ModernaTX, Inc. $545.06 11/28/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042286613
Principal investigator 1 ModernaTX, Inc. $1,070.89 11/28/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042286615
Principal investigator 1 ModernaTX, Inc. $545.06 11/28/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042286617
Principal investigator 1 ModernaTX, Inc. $545.06 11/28/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042286619
Principal investigator 1 ModernaTX, Inc. $1,070.89 11/28/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042286621
Principal investigator 1 ModernaTX, Inc. $1,070.89 11/28/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042286623
Principal investigator 1 ModernaTX, Inc. $545.06 11/28/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042286625
Principal investigator 1 ModernaTX, Inc. $545.06 11/28/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042286627
Principal investigator 1 ModernaTX, Inc. $1,070.89 11/28/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042286629
Principal investigator 1 ModernaTX, Inc. $545.06 11/28/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042286631
Principal investigator 1 ModernaTX, Inc. $1,070.89 11/28/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042286633
Principal investigator 1 ModernaTX, Inc. $545.06 11/28/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042286635
Principal investigator 1 ModernaTX, Inc. $545.06 11/28/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042286637
Principal investigator 1 ModernaTX, Inc. $1,070.89 11/28/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042286639
Principal investigator 1 ModernaTX, Inc. $1,070.89 11/28/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042286641
Principal investigator 1 ModernaTX, Inc. $1,070.89 11/28/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042286643
Principal investigator 1 ModernaTX, Inc. $545.06 11/28/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042286645
Principal investigator 1 ModernaTX, Inc. $1,070.89 11/28/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042286647
Principal investigator 1 ModernaTX, Inc. $545.06 11/28/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042286649
Principal investigator 1 ModernaTX, Inc. $1,070.89 11/28/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042286651
Principal investigator 1 Genentech, Inc. $7,047.00 11/24/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1040287953
Principal investigator 1 Genentech, Inc. $7,047.00 11/14/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1040288391
Principal investigator 1 Genentech, Inc. $21,141.00 11/09/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1040288247
Principal investigator 1 ModernaTX, Inc. $545.06 10/26/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042285057
Principal investigator 1 ModernaTX, Inc. $545.06 10/26/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042285069
Principal investigator 1 ModernaTX, Inc. $545.06 10/26/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042285071
Principal investigator 1 ModernaTX, Inc. $35.00 10/26/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042285073
Principal investigator 1 ModernaTX, Inc. $545.06 10/26/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042285087
Principal investigator 1 ModernaTX, Inc. $35.00 10/26/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042285113
Principal investigator 1 ModernaTX, Inc. $545.06 10/26/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042285123
Principal investigator 1 ModernaTX, Inc. $545.06 10/26/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042285153
Principal investigator 1 ModernaTX, Inc. $545.06 10/26/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042285155
Principal investigator 1 ModernaTX, Inc. $545.06 10/26/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042285157
Principal investigator 1 ModernaTX, Inc. $545.06 10/26/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042285175
Principal investigator 1 ModernaTX, Inc. $545.06 10/26/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042285187
Principal investigator 1 ModernaTX, Inc. $1,070.89 10/26/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042285203
Principal investigator 1 ModernaTX, Inc. $35.00 10/26/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042285233
Principal investigator 1 ModernaTX, Inc. $545.06 10/26/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042285245
Principal investigator 1 ModernaTX, Inc. $545.06 10/26/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042285283
Principal investigator 1 ModernaTX, Inc. $545.06 10/26/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042285285
Principal investigator 1 ModernaTX, Inc. $545.06 10/26/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042285317
Principal investigator 1 ModernaTX, Inc. $545.06 10/26/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042285319
Principal investigator 1 ModernaTX, Inc. $35.00 10/26/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042285361
Principal investigator 1 ModernaTX, Inc. $545.06 10/26/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042285371
Principal investigator 1 ModernaTX, Inc. $545.06 10/26/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042285373
Principal investigator 1 ModernaTX, Inc. $500.00 10/26/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042285375
Principal investigator 1 ModernaTX, Inc. $545.06 10/26/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042285423
Principal investigator 1 ModernaTX, Inc. $545.06 10/26/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042285527
Principal investigator 1 ModernaTX, Inc. $545.06 10/26/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042285583
Principal investigator 1 ModernaTX, Inc. $545.06 10/26/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042285585
Principal investigator 1 ModernaTX, Inc. $545.06 10/26/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042285587
Principal investigator 1 ModernaTX, Inc. $545.06 10/26/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042285645
Principal investigator 1 ModernaTX, Inc. $545.06 10/26/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042285653
Principal investigator 1 ModernaTX, Inc. $545.06 10/26/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042285785
Principal investigator 1 ModernaTX, Inc. $545.06 10/26/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042285827
Principal investigator 1 ModernaTX, Inc. $545.06 10/26/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042285839
Principal investigator 1 Genentech, Inc. $16,443.00 10/23/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1040287355
Principal investigator 1 Genentech, Inc. $150.00 10/09/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1040287367
Principal investigator 1 ModernaTX, Inc. $545.06 10/06/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042282275
Principal investigator 1 ModernaTX, Inc. $545.06 10/06/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042282277
Principal investigator 1 ModernaTX, Inc. $545.06 10/06/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042282291
Principal investigator 1 ModernaTX, Inc. $545.06 10/06/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042282293
Principal investigator 1 ModernaTX, Inc. $545.06 10/06/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042282295
Principal investigator 1 ModernaTX, Inc. $545.06 10/06/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042282311
Principal investigator 1 ModernaTX, Inc. $545.06 10/06/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042282341
Principal investigator 1 ModernaTX, Inc. $545.06 10/06/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042282343
Principal investigator 1 ModernaTX, Inc. $545.06 10/06/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042282361
Principal investigator 1 ModernaTX, Inc. $545.06 10/06/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042282363
Principal investigator 1 ModernaTX, Inc. $545.06 10/06/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042282365
Principal investigator 1 ModernaTX, Inc. $545.06 10/06/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042282459
Principal investigator 1 ModernaTX, Inc. $545.06 10/06/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042282473
Principal investigator 1 ModernaTX, Inc. $545.06 10/06/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042282489
Principal investigator 1 ModernaTX, Inc. $545.06 10/06/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042282491
Principal investigator 1 ModernaTX, Inc. $545.06 10/06/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042282513
Principal investigator 1 ModernaTX, Inc. $545.06 10/06/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042282515
Principal investigator 1 ModernaTX, Inc. $545.06 10/06/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042282517
Principal investigator 1 ModernaTX, Inc. $545.06 10/06/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042282559
Principal investigator 1 ModernaTX, Inc. $545.06 10/06/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042282595
Principal investigator 1 ModernaTX, Inc. $545.06 10/06/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042282597
Principal investigator 1 ModernaTX, Inc. $545.06 10/06/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042282611
Principal investigator 1 ModernaTX, Inc. $545.06 10/06/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042282625
Principal investigator 1 ModernaTX, Inc. $545.06 10/06/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042282627
Principal investigator 1 ModernaTX, Inc. $545.06 10/06/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042282629
Principal investigator 1 ModernaTX, Inc. $545.06 10/06/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042282635
Principal investigator 1 ModernaTX, Inc. $545.06 10/06/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042282643
Principal investigator 1 ModernaTX, Inc. $545.06 10/06/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042282677
Principal investigator 1 ModernaTX, Inc. $545.06 10/06/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042282683
Principal investigator 1 ModernaTX, Inc. $545.06 10/06/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042282717
Principal investigator 1 ModernaTX, Inc. $545.06 10/06/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042282719
Principal investigator 1 ModernaTX, Inc. $545.06 10/06/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042282721
Principal investigator 1 ModernaTX, Inc. $545.06 10/06/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042282793
Principal investigator 1 ModernaTX, Inc. $545.06 10/06/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042282795
Principal investigator 1 ModernaTX, Inc. $545.06 10/06/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042282797
Principal investigator 1 ModernaTX, Inc. $545.06 10/06/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042282813
Principal investigator 1 ModernaTX, Inc. $1,340.00 10/02/2023 Non-covered Recipient Entity
Critical Care, Pulmonary and Sleep Associates - CCT - Avacare - HyperCore - PPDS
A Phase 3, Partly Randomized, Observer-blind Study to Evaluate the Immunogenicity and Safety of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in High-risk Adults No dispute reported 06/30/2026 1042050223
Principal investigator 1 Novartis Pharmaceuticals Corporation $14,000.00 09/19/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Randomized, Participant- and Investigator-blinded, Placebo-controlled Study to Investigate Efficacy, Safety, and Tolerability of LTP001 in Participants With Pulmonary Arterial Hypertension No dispute reported 06/30/2026 1017225021
Principal investigator 1 ModernaTX, Inc. $270.00 09/04/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042279637
Principal investigator 1 ModernaTX, Inc. $101.25 09/04/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042279699
Principal investigator 1 ModernaTX, Inc. $270.00 09/04/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042279727
Principal investigator 1 ModernaTX, Inc. $101.25 09/04/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042279821
Principal investigator 1 Mylan Specialty L.P. $1,116.00 09/01/2023 Non-covered Recipient Entity
Cognitive Clinical Trials
A Phase 4, Randomized, Double-Blind, Double-Dummy, Parallel Group Study Comparing Improvements in Lung Function in Adults With Severe to Very Severe Chronic Obstructive Pulmonary Disease and Suboptimal Inspiratory Flow Rate Following Once-Daily Treatment Over 12 Weeks With Either Revefenacin Inhalation Solution Delivered via Standard Jet Nebulizer or Tiotropium Delivered via a Dry Powder Inhaler (Spiriva HandiHaler) No dispute reported 06/30/2026 1038208817
Principal investigator 1 ModernaTX, Inc. $101.25 08/28/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042257051
Principal investigator 1 ModernaTX, Inc. $270.00 08/28/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042257053
Principal investigator 1 ModernaTX, Inc. $270.00 08/28/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042257055
Principal investigator 1 ModernaTX, Inc. $270.00 08/28/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042257057
Principal investigator 1 ModernaTX, Inc. $270.00 08/28/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042257135
Principal investigator 1 ModernaTX, Inc. $270.00 08/28/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042257235
Principal investigator 1 ModernaTX, Inc. $270.00 08/28/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042257237
Principal investigator 1 ModernaTX, Inc. $270.00 08/28/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042257381
Principal investigator 1 ModernaTX, Inc. $270.00 08/28/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042257383
Principal investigator 1 ModernaTX, Inc. $270.00 08/28/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042257479
Principal investigator 1 ModernaTX, Inc. $101.25 08/28/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042257481
Principal investigator 1 ModernaTX, Inc. $270.00 08/28/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042257507
Principal investigator 1 ModernaTX, Inc. $270.00 08/28/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042257509
Principal investigator 1 ModernaTX, Inc. $270.00 08/28/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042257611
Principal investigator 1 ModernaTX, Inc. $101.25 08/28/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042257613
Principal investigator 1 ModernaTX, Inc. $270.00 08/28/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042257677
Principal investigator 1 ModernaTX, Inc. $101.25 08/28/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042257679
Principal investigator 1 ModernaTX, Inc. $270.00 08/28/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042257721
Principal investigator 1 ModernaTX, Inc. $270.00 08/28/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042257723
Principal investigator 1 ModernaTX, Inc. $270.00 08/28/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042257725
Principal investigator 1 ModernaTX, Inc. $101.25 08/28/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042257771
Principal investigator 1 ModernaTX, Inc. $270.00 08/28/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042257773
Principal investigator 1 ModernaTX, Inc. $270.00 08/28/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042257891
Principal investigator 1 ModernaTX, Inc. $101.25 08/28/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042257893
Principal investigator 1 ModernaTX, Inc. $101.25 08/28/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042257895
Principal investigator 1 ModernaTX, Inc. $270.00 08/28/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042257959
Principal investigator 1 ModernaTX, Inc. $101.25 08/28/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042257961
Principal investigator 1 Genentech, Inc. $2,736.00 08/21/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1040286305
Principal investigator 1 Genentech, Inc. $2,349.00 08/21/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1040286785
Principal investigator 1 ModernaTX, Inc. $500.00 08/18/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042256809
Principal investigator 1 ModernaTX, Inc. $500.00 08/18/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042256857
Principal investigator 1 ModernaTX, Inc. $20.25 08/18/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042256885
Principal investigator 1 ModernaTX, Inc. $500.00 08/18/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042256887
Principal investigator 1 ModernaTX, Inc. $500.00 08/18/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042257167
Principal investigator 1 ModernaTX, Inc. $20.25 08/18/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042257173
Principal investigator 1 ModernaTX, Inc. $500.00 08/18/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042257175
Principal investigator 1 ModernaTX, Inc. $500.00 08/18/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042257191
Principal investigator 1 ModernaTX, Inc. $140.00 08/18/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042257199
Principal investigator 1 ModernaTX, Inc. $500.00 08/18/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042257201
Principal investigator 1 Genentech, Inc. $750.00 08/14/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1040286337
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $160,086.35 08/10/2023 Non-covered Recipient Entity
Cognitive Clinical Trials
Low Intervention Cough Monitoring Study in PPF IPF No dispute reported 06/30/2026 1022134715
Principal investigator 1 ModernaTX, Inc. $545.06 08/09/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042256027
Principal investigator 1 ModernaTX, Inc. $545.06 08/09/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042256029
Principal investigator 1 ModernaTX, Inc. $545.06 08/09/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042256031
Principal investigator 1 ModernaTX, Inc. $545.06 08/09/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042256033
Principal investigator 1 ModernaTX, Inc. $1,173.49 08/09/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042256035
Principal investigator 1 ModernaTX, Inc. $545.06 08/09/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042256063
Principal investigator 1 ModernaTX, Inc. $545.06 08/09/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042256065
Principal investigator 1 ModernaTX, Inc. $545.06 08/09/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042256067
Principal investigator 1 ModernaTX, Inc. $545.06 08/09/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042256069
Principal investigator 1 ModernaTX, Inc. $545.06 08/09/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042256089
Principal investigator 1 ModernaTX, Inc. $545.06 08/09/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042256091
Principal investigator 1 ModernaTX, Inc. $545.06 08/09/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042256093
Principal investigator 1 ModernaTX, Inc. $545.06 08/09/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042256153
Principal investigator 1 ModernaTX, Inc. $545.06 08/09/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042256155
Principal investigator 1 ModernaTX, Inc. $1,173.49 08/09/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042256187
Principal investigator 1 ModernaTX, Inc. $545.06 08/09/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042256189
Principal investigator 1 ModernaTX, Inc. $545.06 08/09/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042256191
Principal investigator 1 ModernaTX, Inc. $545.06 08/09/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042256213
Principal investigator 1 ModernaTX, Inc. $1,173.49 08/09/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042256215
Principal investigator 1 ModernaTX, Inc. $2,878.02 08/09/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042256217
Principal investigator 1 ModernaTX, Inc. $545.06 08/09/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042256219
Principal investigator 1 ModernaTX, Inc. $545.06 08/09/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042256265
Principal investigator 1 ModernaTX, Inc. $2,878.02 08/09/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042256267
Principal investigator 1 ModernaTX, Inc. $545.06 08/09/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042256269
Principal investigator 1 ModernaTX, Inc. $545.06 08/09/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042256271
Principal investigator 1 ModernaTX, Inc. $545.06 08/09/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042256273
Principal investigator 1 ModernaTX, Inc. $545.06 08/09/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042256275
Principal investigator 1 ModernaTX, Inc. $545.06 08/09/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042256295
Principal investigator 1 ModernaTX, Inc. $545.06 08/09/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042256297
Principal investigator 1 ModernaTX, Inc. $545.06 08/09/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042256299
Principal investigator 1 ModernaTX, Inc. $545.06 08/09/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042256345
Principal investigator 1 ModernaTX, Inc. $545.06 08/09/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042256381
Principal investigator 1 ModernaTX, Inc. $545.06 08/09/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042256383
Principal investigator 1 ModernaTX, Inc. $545.06 08/09/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042256417
Principal investigator 1 ModernaTX, Inc. $545.06 08/09/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042256419
Principal investigator 1 ModernaTX, Inc. $545.06 08/09/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042256421
Principal investigator 1 ModernaTX, Inc. $2,878.02 08/09/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042256423
Principal investigator 1 ModernaTX, Inc. $545.06 08/09/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042256425
Principal investigator 1 ModernaTX, Inc. $545.06 08/09/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042256451
Principal investigator 1 ModernaTX, Inc. $545.06 08/09/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042256453
Principal investigator 1 ModernaTX, Inc. $545.06 08/09/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042256455
Principal investigator 1 ModernaTX, Inc. $545.06 08/09/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042256457
Principal investigator 1 ModernaTX, Inc. $545.06 08/09/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042256459
Principal investigator 1 ModernaTX, Inc. $545.06 08/09/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042256461
Principal investigator 1 ModernaTX, Inc. $2,878.02 08/09/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042256487
Principal investigator 1 ModernaTX, Inc. $545.06 08/09/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042256489
Principal investigator 1 ModernaTX, Inc. $1,173.49 08/09/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042256491
Principal investigator 1 ModernaTX, Inc. $545.06 08/09/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042256493
Principal investigator 1 ModernaTX, Inc. $2,878.02 08/09/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042256495
Principal investigator 1 ModernaTX, Inc. $545.06 08/09/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042256523
Principal investigator 1 ModernaTX, Inc. $545.06 08/09/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042256525
Principal investigator 1 ModernaTX, Inc. $545.06 08/09/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042256527
Principal investigator 1 ModernaTX, Inc. $545.06 08/09/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042256597
Principal investigator 1 ModernaTX, Inc. $545.06 08/09/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042256599
Principal investigator 1 ModernaTX, Inc. $545.06 08/09/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042256601
Principal investigator 1 ModernaTX, Inc. $545.06 08/09/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042256603
Principal investigator 1 ModernaTX, Inc. $545.06 08/09/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042256605
Principal investigator 1 ModernaTX, Inc. $545.06 08/09/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042256701
Principal investigator 1 ModernaTX, Inc. $545.06 08/09/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042256703
Principal investigator 1 ModernaTX, Inc. $545.06 08/09/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042256705
Principal investigator 1 ModernaTX, Inc. $545.06 08/09/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042256707
Principal investigator 1 ModernaTX, Inc. $545.06 08/09/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042256783
Principal investigator 1 ModernaTX, Inc. $545.06 08/09/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042256785
Principal investigator 1 ModernaTX, Inc. $545.06 08/09/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042256787
Principal investigator 1 ModernaTX, Inc. $545.06 08/09/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042256789
Principal investigator 1 ModernaTX, Inc. $545.06 08/09/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042256791
Principal investigator 1 ModernaTX, Inc. $545.06 08/09/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042256793
Principal investigator 1 ModernaTX, Inc. $545.06 08/09/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042256795
Principal investigator 1 ModernaTX, Inc. $2,878.02 08/09/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042256797
Principal investigator 1 ModernaTX, Inc. $545.06 08/09/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042256799
Principal investigator 1 Genentech, Inc. $900.00 07/06/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1040284255
Principal investigator 1 ModernaTX, Inc. $647.66 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042253805
Principal investigator 1 ModernaTX, Inc. $2,878.02 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042253807
Principal investigator 1 ModernaTX, Inc. $2,225.14 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042253809
Principal investigator 1 ModernaTX, Inc. $647.66 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042253811
Principal investigator 1 ModernaTX, Inc. $647.66 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042253813
Principal investigator 1 ModernaTX, Inc. $2,878.02 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042253815
Principal investigator 1 ModernaTX, Inc. $647.66 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042253817
Principal investigator 1 ModernaTX, Inc. $1,173.49 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042253819
Principal investigator 1 ModernaTX, Inc. $1,391.51 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042253821
Principal investigator 1 ModernaTX, Inc. $647.66 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042253823
Principal investigator 1 ModernaTX, Inc. $2,878.02 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042253825
Principal investigator 1 ModernaTX, Inc. $1,391.51 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042253827
Principal investigator 1 ModernaTX, Inc. $2,878.02 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042253829
Principal investigator 1 ModernaTX, Inc. $1,173.49 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042253831
Principal investigator 1 ModernaTX, Inc. $2,878.02 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042253833
Principal investigator 1 ModernaTX, Inc. $2,878.02 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042253835
Principal investigator 1 ModernaTX, Inc. $2,878.02 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042253837
Principal investigator 1 ModernaTX, Inc. $1,391.51 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042253839
Principal investigator 1 ModernaTX, Inc. $1,391.51 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042253841
Principal investigator 1 ModernaTX, Inc. $1,173.49 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042253843
Principal investigator 1 ModernaTX, Inc. $2,878.02 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042253845
Principal investigator 1 ModernaTX, Inc. $2,878.02 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042253847
Principal investigator 1 ModernaTX, Inc. $2,878.02 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042253849
Principal investigator 1 ModernaTX, Inc. $2,225.14 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042253851
Principal investigator 1 ModernaTX, Inc. $1,391.51 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042253853
Principal investigator 1 ModernaTX, Inc. $1,173.49 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042253855
Principal investigator 1 ModernaTX, Inc. $647.66 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042253857
Principal investigator 1 ModernaTX, Inc. $2,878.02 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042253859
Principal investigator 1 ModernaTX, Inc. $1,391.51 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042253861
Principal investigator 1 ModernaTX, Inc. $2,225.14 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042253863
Principal investigator 1 ModernaTX, Inc. $647.66 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042253865
Principal investigator 1 ModernaTX, Inc. $2,878.02 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042253867
Principal investigator 1 ModernaTX, Inc. $1,391.51 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042253869
Principal investigator 1 ModernaTX, Inc. $2,225.14 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042253871
Principal investigator 1 ModernaTX, Inc. $2,225.14 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042253873
Principal investigator 1 ModernaTX, Inc. $1,173.49 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042253875
Principal investigator 1 ModernaTX, Inc. $647.66 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042253877
Principal investigator 1 ModernaTX, Inc. $2,225.14 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042253879
Principal investigator 1 ModernaTX, Inc. $2,225.14 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042253881
Principal investigator 1 ModernaTX, Inc. $1,173.49 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042253883
Principal investigator 1 ModernaTX, Inc. $647.66 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042253885
Principal investigator 1 ModernaTX, Inc. $2,225.14 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042253887
Principal investigator 1 ModernaTX, Inc. $1,391.51 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042253889
Principal investigator 1 ModernaTX, Inc. $1,391.51 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042253891
Principal investigator 1 ModernaTX, Inc. $1,391.51 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042253893
Principal investigator 1 ModernaTX, Inc. $2,225.14 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042253895
Principal investigator 1 ModernaTX, Inc. $647.66 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042253897
Principal investigator 1 ModernaTX, Inc. $2,878.02 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042253899
Principal investigator 1 ModernaTX, Inc. $647.66 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042253901
Principal investigator 1 ModernaTX, Inc. $1,391.51 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042253903
Principal investigator 1 ModernaTX, Inc. $2,878.02 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042253905
Principal investigator 1 ModernaTX, Inc. $1,173.49 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042253907
Principal investigator 1 ModernaTX, Inc. $2,225.14 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042253909
Principal investigator 1 ModernaTX, Inc. $1,173.49 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042253911
Principal investigator 1 ModernaTX, Inc. $2,225.14 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042253913
Principal investigator 1 ModernaTX, Inc. $2,225.14 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042253915
Principal investigator 1 ModernaTX, Inc. $647.66 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042253917
Principal investigator 1 ModernaTX, Inc. $2,878.02 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042253919
Principal investigator 1 ModernaTX, Inc. $2,225.14 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042253921
Principal investigator 1 ModernaTX, Inc. $1,391.51 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042253923
Principal investigator 1 ModernaTX, Inc. $1,173.49 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042253925
Principal investigator 1 ModernaTX, Inc. $2,225.14 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042253927
Principal investigator 1 ModernaTX, Inc. $2,225.14 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042253929
Principal investigator 1 ModernaTX, Inc. $2,878.02 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042253931
Principal investigator 1 ModernaTX, Inc. $1,173.49 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042253933
Principal investigator 1 ModernaTX, Inc. $1,173.49 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042253935
Principal investigator 1 ModernaTX, Inc. $2,225.14 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042253937
Principal investigator 1 ModernaTX, Inc. $1,173.49 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042253939
Principal investigator 1 ModernaTX, Inc. $1,391.51 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042253941
Principal investigator 1 ModernaTX, Inc. $1,173.49 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042253943
Principal investigator 1 ModernaTX, Inc. $1,173.49 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042253945
Principal investigator 1 ModernaTX, Inc. $2,225.14 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042253947
Principal investigator 1 ModernaTX, Inc. $1,391.51 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042253949
Principal investigator 1 ModernaTX, Inc. $647.66 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042253951
Principal investigator 1 ModernaTX, Inc. $2,878.02 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042254005
Principal investigator 1 ModernaTX, Inc. $1,173.49 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042254007
Principal investigator 1 ModernaTX, Inc. $647.66 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042254009
Principal investigator 1 ModernaTX, Inc. $2,878.02 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042254011
Principal investigator 1 ModernaTX, Inc. $1,391.51 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042254013
Principal investigator 1 ModernaTX, Inc. $1,173.49 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042254015
Principal investigator 1 ModernaTX, Inc. $1,173.49 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042254017
Principal investigator 1 ModernaTX, Inc. $2,225.14 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042254019
Principal investigator 1 ModernaTX, Inc. $2,878.02 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042254021
Principal investigator 1 ModernaTX, Inc. $1,173.49 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042254023
Principal investigator 1 ModernaTX, Inc. $2,225.14 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042254025
Principal investigator 1 ModernaTX, Inc. $2,878.02 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042254027
Principal investigator 1 ModernaTX, Inc. $2,225.14 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042254029
Principal investigator 1 ModernaTX, Inc. $2,878.02 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042254031
Principal investigator 1 ModernaTX, Inc. $647.66 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042254033
Principal investigator 1 ModernaTX, Inc. $1,391.51 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042254035
Principal investigator 1 ModernaTX, Inc. $1,173.49 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042254037
Principal investigator 1 ModernaTX, Inc. $647.66 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042254039
Principal investigator 1 ModernaTX, Inc. $2,225.14 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042254041
Principal investigator 1 ModernaTX, Inc. $2,878.02 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042254043
Principal investigator 1 ModernaTX, Inc. $1,173.49 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042254045
Principal investigator 1 ModernaTX, Inc. $647.66 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042254047
Principal investigator 1 ModernaTX, Inc. $2,225.14 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042254049
Principal investigator 1 ModernaTX, Inc. $1,391.51 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042254051
Principal investigator 1 ModernaTX, Inc. $2,878.02 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042254053
Principal investigator 1 ModernaTX, Inc. $2,878.02 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042254055
Principal investigator 1 ModernaTX, Inc. $647.66 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042254057
Principal investigator 1 ModernaTX, Inc. $2,878.02 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042254059
Principal investigator 1 ModernaTX, Inc. $1,391.51 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042254061
Principal investigator 1 ModernaTX, Inc. $647.66 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042254063
Principal investigator 1 ModernaTX, Inc. $1,391.51 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042254065
Principal investigator 1 ModernaTX, Inc. $647.66 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042254067
Principal investigator 1 ModernaTX, Inc. $2,878.02 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042254069
Principal investigator 1 ModernaTX, Inc. $647.66 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042254071
Principal investigator 1 ModernaTX, Inc. $647.66 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042254073
Principal investigator 1 ModernaTX, Inc. $2,225.14 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042254075
Principal investigator 1 ModernaTX, Inc. $647.66 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042254077
Principal investigator 1 ModernaTX, Inc. $647.66 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042254079
Principal investigator 1 ModernaTX, Inc. $1,173.49 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042254081
Principal investigator 1 ModernaTX, Inc. $647.66 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042254083
Principal investigator 1 ModernaTX, Inc. $2,225.14 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042254085
Principal investigator 1 ModernaTX, Inc. $2,878.02 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042254087
Principal investigator 1 ModernaTX, Inc. $1,391.51 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042254089
Principal investigator 1 ModernaTX, Inc. $2,878.02 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042254091
Principal investigator 1 ModernaTX, Inc. $1,173.49 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042254093
Principal investigator 1 ModernaTX, Inc. $2,225.14 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042254095
Principal investigator 1 ModernaTX, Inc. $1,391.51 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042254097
Principal investigator 1 ModernaTX, Inc. $647.66 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042254099
Principal investigator 1 ModernaTX, Inc. $2,878.02 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042254101
Principal investigator 1 ModernaTX, Inc. $2,225.14 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042254103
Principal investigator 1 ModernaTX, Inc. $647.66 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042254105
Principal investigator 1 ModernaTX, Inc. $2,878.02 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042254107
Principal investigator 1 ModernaTX, Inc. $647.66 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042254109
Principal investigator 1 ModernaTX, Inc. $1,391.51 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042254111
Principal investigator 1 ModernaTX, Inc. $647.66 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042254113
Principal investigator 1 ModernaTX, Inc. $2,225.14 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042254115
Principal investigator 1 ModernaTX, Inc. $1,391.51 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042254117
Principal investigator 1 ModernaTX, Inc. $1,173.49 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042254119
Principal investigator 1 ModernaTX, Inc. $2,225.14 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042254121
Principal investigator 1 ModernaTX, Inc. $647.66 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042254123
Principal investigator 1 ModernaTX, Inc. $2,878.02 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042254125
Principal investigator 1 ModernaTX, Inc. $647.66 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042254127
Principal investigator 1 ModernaTX, Inc. $2,878.02 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042254129
Principal investigator 1 ModernaTX, Inc. $1,391.51 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042254131
Principal investigator 1 ModernaTX, Inc. $2,225.14 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042254133
Principal investigator 1 ModernaTX, Inc. $647.66 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042254135
Principal investigator 1 ModernaTX, Inc. $1,173.49 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042254137
Principal investigator 1 ModernaTX, Inc. $2,225.14 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042254139
Principal investigator 1 ModernaTX, Inc. $1,391.51 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042254141
Principal investigator 1 ModernaTX, Inc. $2,878.02 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042254143
Principal investigator 1 ModernaTX, Inc. $2,225.14 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042254145
Principal investigator 1 ModernaTX, Inc. $2,878.02 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042254147
Principal investigator 1 ModernaTX, Inc. $647.66 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042254149
Principal investigator 1 ModernaTX, Inc. $2,225.14 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042254151
Principal investigator 1 ModernaTX, Inc. $1,391.51 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042254153
Principal investigator 1 ModernaTX, Inc. $2,878.02 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042254155
Principal investigator 1 ModernaTX, Inc. $1,391.51 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042254157
Principal investigator 1 ModernaTX, Inc. $2,878.02 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042254159
Principal investigator 1 ModernaTX, Inc. $1,391.51 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042254161
Principal investigator 1 ModernaTX, Inc. $1,391.51 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042254163
Principal investigator 1 ModernaTX, Inc. $1,391.51 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042254165
Principal investigator 1 ModernaTX, Inc. $1,173.49 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042254167
Principal investigator 1 ModernaTX, Inc. $1,391.51 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042254169
Principal investigator 1 ModernaTX, Inc. $1,391.51 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042254171
Principal investigator 1 ModernaTX, Inc. $1,173.49 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042254173
Principal investigator 1 ModernaTX, Inc. $1,391.51 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042254175
Principal investigator 1 ModernaTX, Inc. $1,173.49 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042254177
Principal investigator 1 ModernaTX, Inc. $1,173.49 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042254179
Principal investigator 1 ModernaTX, Inc. $2,225.14 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042254181
Principal investigator 1 ModernaTX, Inc. $2,225.14 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042254183
Principal investigator 1 ModernaTX, Inc. $1,173.49 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042254185
Principal investigator 1 ModernaTX, Inc. $647.66 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042254187
Principal investigator 1 ModernaTX, Inc. $1,173.49 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042254189
Principal investigator 1 ModernaTX, Inc. $2,225.14 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042254191
Principal investigator 1 ModernaTX, Inc. $647.66 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042254193
Principal investigator 1 ModernaTX, Inc. $2,878.02 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042254195
Principal investigator 1 ModernaTX, Inc. $1,391.51 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042254197
Principal investigator 1 ModernaTX, Inc. $1,391.51 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042254199
Principal investigator 1 ModernaTX, Inc. $647.66 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042254201
Principal investigator 1 ModernaTX, Inc. $1,391.51 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042254203
Principal investigator 1 ModernaTX, Inc. $1,173.49 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042254205
Principal investigator 1 ModernaTX, Inc. $1,173.49 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042254207
Principal investigator 1 ModernaTX, Inc. $2,225.14 06/30/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042254209
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $887.20 06/27/2023 Non-covered Recipient Entity
Critical Care Pulmonary And Sleep Associates Professional LLP
Low Intervention Cough Monitoring Study in PPF IPF No dispute reported 06/30/2026 1007440201
Principal investigator 1 Mylan Specialty L.P. $13,324.00 06/05/2023 Non-covered Recipient Entity
Cognitive Clinical Trials
A Phase 4, Randomized, Double-Blind, Double-Dummy, Parallel Group Study Comparing Improvements in Lung Function in Adults With Severe to Very Severe Chronic Obstructive Pulmonary Disease and Suboptimal Inspiratory Flow Rate Following Once-Daily Treatment Over 12 Weeks With Either Revefenacin Inhalation Solution Delivered via Standard Jet Nebulizer or Tiotropium Delivered via a Dry Powder Inhaler (Spiriva HandiHaler) No dispute reported 06/30/2026 1038208811
Principal investigator 1 Boehringer Ingelheim International GmbH $4,084.35 06/01/2023 Non-covered Recipient Entity
Critical Care Pulmonary And Sleep Associates Professional LLP
Low Intervention Cough Monitoring Study in PPF IPF No dispute reported 06/30/2026 1007645349
Principal investigator 1 ModernaTX, Inc. $1,340.00 06/01/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042250541
Principal investigator 1 ModernaTX, Inc. $10,000.00 06/01/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042250543
Principal investigator 1 ModernaTX, Inc. $8,000.00 06/01/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042250545
Principal investigator 1 ModernaTX, Inc. $2,500.00 06/01/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042250547
Principal investigator 1 Genentech, Inc. $13,500.00 05/29/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1040283725
Principal investigator 1 ModernaTX, Inc. $33.64 04/21/2023 Non-covered Recipient Entity
CRITICAL CARE PULMONARY&SLEEP ASSOC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041563853
Principal investigator 1 ModernaTX, Inc. $8,650.00 04/20/2023 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1042241535
Principal investigator 1 ModernaTX, Inc. $33.64 03/14/2023 Non-covered Recipient Entity
CRITICAL CARE PULMONARY&SLEEP ASSOC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041563669
Principal investigator 1 ModernaTX, Inc. $102.00 03/13/2023 Non-covered Recipient Entity
CRITICAL CARE PULMONARY&SLEEP ASSOC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041563683